Should You Continue to Retain Bio-Techne Stock in Your Portfolio?

Bio-Techne (TECH) is making notable strides in its four growth verticals, which are poised to help it grow in the upcoming quarters. The company is now pursuing clinical diagnostic opportunities on the Ella platform after achieving the ISO 13485 certification. Acquisitions have continued to play an important role in Bio-Techne’s efforts to expand its portfolio and enter adjacent markets. However, adverse macroeconomic impacts and intense rivalry raise concerns for its operations.In the past year, shares of ...